HealthEquity's AI Flywheel: Margin Expansion and a $1B Buyback Signal a New Phase
Marketplace (Mark) adoption, fraud costs collapsing, and AI-driven efficiency lift margins while management raises FY27 guidance.
HQY · Earnings Call · 2026-05-28
HealthEquity's fiscal Q1 2027 results, reported on May 28, were not just a beat — they were a declaration that the platform's largest investment cycle has crossed an inflection point. Revenue grew 7% to $355M, adjusted EBITDA margin hit 46%, and management raised full-year guidance while adding $1B to the buyback. The stock has gained 35% over the past 90 days, reflecting a market beginning to re-rate the company from a custodian to a technology-enabled services asset.
The AI cost curve becomes visible
The margin expansion was driven by a visible step-change in automation. “We delivered higher profitability, expanded adjusted EBITDA margin to 46%, and are raising our fiscal 27 guidance.” — Scott R. Cutler, President and CEO · 2026-05-28 The mechanics: “AI driven tools reduced manual handling of member and client service emails by 25%... and accelerated processing times by up to 50%.” — Scott R. Cutler, President and CEO · 2026-05-28 Fraud reimbursements — the cleanest metric of operational improvement — dropped from $3.2M to $300K year-on-year. That's not luck; it's a deliberately engineered AI enabled service stack. The gross margin moved from 67.5% to 72.3%, a 4.5pp expansion, while operating income grew 24% to $103M. 72.3% The company is getting more efficient with every incremental member, and the forward-looking Fed rate lock has reduced yield volatility, making EBITDA guidance more dependable.
Prior management commentary had telegraphed this trajectory. Just two months earlier they were already showing the mechanics: “We are at or below our target run rate there.” — Scott Cutler, President and CEO · 2026-03-17 That was about fraud costs; today the entire service cost line is responding. The self service migration, driven by app adoption and passkey authentication, is a direct cost lever. Management's earlier diagnosis — "we are at the very beginning of our journey on AI" — is now showing up in the numbers.
Certain targeted workflows such as card servicing and claims inquiries, AI enabled automation reduced manual efforts by more than 90% and accelerated processing times by up to 50%.
Mark: the marketplace flywheel gains altitude
The bigger strategic change is the consumer marketplace, branded Mark. Management says “there is really no gating function because it is not a channel that is dependent on marketing spend like other ecommerce sites would be.” — Scott R. Cutler, President and CEO · 2026-05-28 In the quarter, Mark crossed 10,000+ members and added new categories (TRT, diagnostics). That may sound small, but the economics are different: weight loss and TRT programs carry fees of $90–100 and $50+ per participating member per month, respectively. “Mark is helping more than 10 thousand+ members access health related programs and products.” — Scott R. Cutler, President and CEO · 2026-05-28 This is the beginning of a distinct lifetime value expansion engine. The prior quarter's launch was deliberately narrow — "we have only really got three programs in weight loss and in hormone replacement and then in the wearables category" — and now it's scaling without incremental marketing. The weight loss program is the most active, and service revenue, which grew 3% to $123M, already reflects a small but growing attach rate.
Capital allocation and the raised bar
The confidence is showing up in capital allocation. The board added $1B to the share repurchase authorization, and the company bought $123M of stock in Q1 alone. That's consistent with management's view that the market undervalues the cash generation. Operating cash flow was $98M, and free cash flow (less SBC) hit $78M, up 55% yoy. $78M The balance sheet remains modestly leveraged (net debt ~$682M), but the debt is a deliberate consequence of the BenefitWallet acquisition, not a new strain. Raising guidance on both revenue and EBITDA signals management believes the margin trajectory is durable.
The macro caveat
The one soft spot is interchange growth of 5%, slightly below the company's own history. Jim Lucania noted lower transaction per account and average ticket as possible signs of healthcare utilization easing. That's a trend to watch, but the company chose not to call a structural shift. The flywheel — account growth, asset growth, and engagement — still compounds. With HSA assets up 19% and invested assets up 38%, the platform is capturing more of the member's financial life. The bronze plan expansion remains an early option. For now, the story is clear: HealthEquity is converting AI investment into margin, and Mark into a new revenue line. The market is starting to pay attention.